Research Use Only Not for Human Consumption
Clinically meaningful responses in insulin-resistant patients typically include a reduction in fasting insulin of 20-40% and an improvement in HOMA-IR within 8-12 weeks at therapeutic doses, though individual variability is wide [1]
Tesamorelin is the exception, and that distinction matters more than most people realize
declares having received honoraria from Novo Nordisk, Eli Lilly, Akebia Therapeutics, Ardelyx, Becton Dickinson, Endologix, FibroGen, GSK, Medtronic, Neovasc, Provention Bio, ReCor, BrainStorm Cell Therapeutics, Alnylam and Intarcia for consulting activities, and research funding to his institution from AbbVie, Esperion, AstraZeneca, CSL Behring, Novartis and Eli Lilly
Sublingual delivery faces the same absorption barrier: At 29 amino acids, sermorelin is too large for reliable mucosal absorption
This mechanism explains why users often report improvements in stubborn fat deposits that had not responded adequately to diet and exercise alone